A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase Ⅲ Clinical Trial of Yiqi Wenjing Prescriptions for Preventing Oxaliplatin-induced Peripheral Neuropathy

This study is a randomized, placebo-controlled, double-blind, multicenter phase III clinical trial of Yiqi Wenjing prescriptions for Preventing Oxaliplatin-induced Peripheral Neuropathy.

开始日期2021-01-01

申办/合作机构

Nanjing NingQi Medicine Science and Technology Co., Ltd.

[+4]

NCT05566457 / Recruiting临床2期IIT

Clinical Study of Huangshi Guizhi Wuwu Decoction in Improving the Paclitaxel-related Neurotoxicity in Breast Cancer Patients

The current treatments for albumin-bound paclitaxel (nab-PTX) -related peripheral neurotoxicity (PN) mainly included cryotherapy and compression therapy , oral B group vitamin , and duloxetine. However, treatment effectiveness of these three methods is limited. Huangqi Guizhi Wuwu decoction (HGWD) is an herbal formula recorded in "Synopsis of the Golden Chamber" for improving limb pain, tingling, and numbness, which is composed of five crude drugs (Astragali Radix, Cinnamomi Ramulus, Paeoniae Radix Alba, Zingiberis Rhizoma Recens, and Jujubae Fructus)(9). Recently, HGWD has been shown to be effective in the treatment of oxaliplatin- and diabetic-related PNs . But there are no prospective studies to explore the efficacy of HGWD in the treatment of nab-PTX-induced PN in patients with BC. Therefore, we conducted this prospective randomized controlled study to investigate the efficacy and safety of HGWD to prevent nab-PTX-induced PN in patients with BC. The primary aim of this study was to assess the prevention of nab-PTX-induced PN by soaking hands and/or feet with HGWD when compared to placebo.

开始日期2020-01-01

申办/合作机构

中国医学科学院

NCT01553643 / Unknown status临床4期IIT

A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis

Intracranial arterial prominent stenosis (IAPS) is one of main cause of stroke especially in Asia. Although antiplatelet aggregative or anticoagulant agent and even surgical operation are used to treat patients with IAPS, the incidence of stroke occurrence still remains high. In addition, symptomatic IAPS most common cause continuous deterioration, thus, increase the incidence of stroke. Therefore, there is a good method to reduce the inceidence of stroke that is to prevent the progressive deterioration of IAPS.
Huang-Chi-Wu-Wu-Tang is made of Astrgalus membranaceus (Fisch.) Gge , Paeonia lactiflora Pall , Cinnamom Twig , Zingiber officinale Rose , Ziziphus jujube Mill , and can treat hemiplegia in the traditional Chinese medicine writings. Astragaloside IV is a component of Astrgalus membranaceus, may reduce th cerebral infarction area in middle cerebral arterial occlusion mice. The investigators previous studies have known that paeoniflorin that a component of Paeonia lactiflora Pall can decrease the cerebral infarction area and neurological deficit in middle cerebral arterial occlusion rats. Therefore, the purpose of the present study was to investigate the effect of Huang-Chi-Wu-Wu-Tang on patients with IAPS.

开始日期2010-01-01

申办/合作机构

中国医药大学附设医院

100 项与黄芪桂枝五物汤相关的临床结果

登录后查看更多信息

100 项与黄芪桂枝五物汤相关的转化医学

登录后查看更多信息

100 项与黄芪桂枝五物汤相关的专利（医药）

登录后查看更多信息

项与黄芪桂枝五物汤相关的文献（医药）

2024-09-01·Combinatorial Chemistry & High Throughput Screening

Effect and Mechanisms of Huangqi-Shanzhuyu in the Treatment of Diabetic Nephropathy based on Network Pharmacology and In Vitro Experiments

Article

作者: Liu, Chao ; Ma, Yinghua ; Zhang, Guying ; Yuan, Shizhao ; Han, Yu ; Zhao, Yile ; Wei, Shufei ; Nie, Ying

Background::Huangqi-Shanzhuyu (HS), a classic combination of Chinese herbal formulae, has been widely used for the treatment of diabetic nephropathy (DN). However, its pharmacological mechanism of action is still unclear.Methods::The active ingredients of HS and their potential targets were identified through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and the DN-related targets were determined from GeneCards, Online Mendelian Inheritance in Man (OMIM), PharmGkb, and Therapeutic Target Database (TTD). The Cytoscape software was used to construct a herb-disease-target network and screen core genes. STRING was employed to generate a protein-protein interaction (PPI) network. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to predict the mechanism of action of HS in DN. Animal experiments and molecular docking were used to verify the potential mechanism.Results::In total, 40 active ingredients and 180 effective targets of HS in DN were identified and 1115 DN-related targets were retrieved. From the PPI network, VEGFA, AKT1, IL6, IL1B, TP53, MMP9, PTGS2, CASP3, EGF and EGFR were identified as core genes. The anti-DN mechanism mainly involved multiple signaling pathways such as AGEs-RAGE. Animal experiments and molecular docking analysis confirmed that HS downregulated the expression of IL-1 and IL-6 via kaempferol-mediated inhibition of JNK1 phosphorylation.Conclusions::HS exhibits a therapeutic effect in DN through its multiple ingredients that act on several targets and multiple signaling pathways, including AGEs-RAGE.

2019-03-01·Medicine4区 · 医学

A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Huangqi Guizhi Wuwutang granule in patients with rheumatoid arthritis

4区 · 医学

ArticleOA

作者: Wang, Yiru ; Yao, Min ; Mao, Jianchun ; Xi, Zhijie ; Liu, Li ; Cui, Xuejun ; Shi, Qi ; Wang, Yongjun ; Yu, Yang ; Liu, Yang ; Liang, Qianqian ; Xiao, Lianbo ; Gu, Xiaohua

AbstractBackground:Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by swelling, pain, and synovial damage. Effective methods lack in the treatment of RA. A traditional prescription in use for thousands of years in China, Huangqi Guizhi Wuwutang granule (HGWG) is still chosen to relieve pain and prevent joint malformation in RA patients. However, no evidence-based medical research has been organized to assess the effectiveness and safety of HGWG for RA.Methods/design:We will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to determine whether HGWG can relieve pain and protect joints. We will randomly divide 120 patients with active RA into 2 groups, treated for 12 weeks. Main measurement is the rate of ACR50 score (American College of Rheumatology) from the baseline to 12 weeks. Secondary measurements include rate of ACR20/70, change of Disease Activity Score (DAS) 28, Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient Assessment of Arthritis Pain, Patient Global Assessment of Arthritis, and AIS score. The time points are set as baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks, and 48 weeks. In addition, the rate of ACR50 from the baseline to 2 weeks, 4 weeks, 8 weeks, 24 weeks, and 48 weeks’ follow-up are also the secondary outcome measures.Discussion:The findings of this research will elucidate the efficacy and safety of HGWG and provide an alternative treatment for RA. In addition, our data will benefit the clinical decision-making on active RA and possibly be incorporated into future guidelines.Trial registration:ClinicalTrials.gov ID: NCT03593837.

项与黄芪桂枝五物汤相关的新闻（医药）

2022-09-29

·蒲公英Ouryao

两局联合发布25个古代经典名方，配方用法

转自：国家中医药管理局编辑：水晶9月27日，国家中医药管理局网讯，国家中医药管理局和国家药品监督管理局联合发布《古代经典名方关键信息表（25首方剂）》，其中包括桃核承气汤、芍药甘草汤和半夏泻心汤等25首方剂。此次发布的25首方剂分别为桃核承气汤、芍药甘草汤、半夏泻心汤、真武汤、黄芪桂枝五物汤、瓜蒌薤白半夏汤、大建中汤、麦门冬汤、温胆汤、小续命汤、开心散、当归饮子、泻白散、清心莲子饮、羌活胜湿汤、当归补血汤、地黄饮子、清金化痰汤、金水六君煎、济川煎、清肺汤、保元汤、半夏白术天麻汤、易黄汤、宣郁通经汤。《古代经典名方关键信息表（25首方剂）》共包括2项基本信息和6项现代对应情况。基本信息包括每首方剂出处和处方、制法及用法，现代对应情况信息则涵盖药味名称、基原及用药部位、炮制规格、折算剂量、用法用量、功能主治等内容。附件：推荐阅读：蒲公英Ouryao视频号我们上线了蒲公英Ouryao视频号，每期3分钟，学习制药英语，用制药点燃你的语言星球。你的每一次“在看”，我都看得见！

100 项与黄芪桂枝五物汤相关的药物交易

登录后查看更多信息